Orthofix to Participate in Upcoming Investor Conferences
[url="]Orthofix Medical Inc[/url]. (NASDAQ: OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following
OFIX - Orthofix Medical Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.60
DETAILS
HIGH:
$18.00
LOW:
$12.00
MEDIAN:
$15.00
CONSENSUS:
$15.60
UPSIDE:
45.12%
Stock News
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Goldman Sachs 47th Annual Global Healthcare Conference - Miami Beach, June 8, 2026, Fireside Chat Time: 8:40 am Eastern Time Truist Securities MedTech Conference - Boston, June 16, 2026, 1x1 Meetings Only Interested parties can access the live and archived webcast of the Goldman Sachs fireside.
Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced new pediatric limb reconstruction innovations that expand treatment options for pediatric and small stature patients. The Company will highlight these advances at the Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting, which takes place May 6-8, 2026, at the Rosen Shingle Creek Hotel in Orlando, Florida. At POSNA 2026, Orthofix will showcas.
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders are encouraged to contact the firm at no cost or obligation.
Orthofix Medical Inc. (OFIX) Q1 2026 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q1 2026 Earnings Call Transcript
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ pr.
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NasdaqGS: OFIX).On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective immediately, following the “unanimous decision by the Board's independent directors.
Orthofix to Report First Quarter 2026 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing th.
Orthofix Medical (NASDAQ:OFIX) Insider Jorge Andres Cedron Sells 3,743 Shares of Stock
Orthofix Medical Inc. (NASDAQ: OFIX - Get Free Report) insider Jorge Andres Cedron sold 3,743 shares of the business's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $12.82, for a total transaction of $47,985.26. Following the transaction, the insider owned 59,006 shares in the company, valued at
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK and NEW ORLEANS, April 17, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Head-To-Head Survey: Vasamed (OTCMKTS:VSMD) vs. Orthofix Medical (NASDAQ:OFIX)
Vasamed (OTCMKTS:VSMD - Get Free Report) and Orthofix Medical (NASDAQ: OFIX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability. Earnings and Valuation This table compares Vasamed and Orthofix
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Orthofix Medical, Inc. (“Orthofix” or the “Company”) (NasdaqGS: OFIX). On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective immediately, following the “unanimous decision by the Board's independent di.
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountabi.
Orthofix Medical Inc. $OFIX Stake Lifted by JPMorgan Chase & Co.
JPMorgan Chase and Co. lifted its stake in shares of Orthofix Medical Inc. (NASDAQ: OFIX) by 33.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 258,035 shares of the medical device company's stock after acquiring an additional 64,486 shares during the
Reviewing Orthofix Medical (NASDAQ:OFIX) and CVRx (NASDAQ:CVRX)
Orthofix Medical (NASDAQ: OFIX - Get Free Report) and CVRx (NASDAQ: CVRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Volatility and Risk Orthofix Medical has a beta
Down 12.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Orthofix (OFIX)
Orthofix (OFIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. If you currently own Orthofix stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your.
OFIX Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical Inc. – OFIX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). If you currently own shares of Orthofix Medical stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=19330 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why R.
Orthofix Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical, Inc. – OFIX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). If you currently own shares of Orthofix Medical stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=19330 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why R.
Orthofix Medical (NASDAQ:OFIX) Shares Gap Up Following Insider Buying Activity
Orthofix Medical Inc. (NASDAQ: OFIX - Get Free Report) shares gapped up prior to trading on Friday after an insider bought additional shares in the company. The stock had previously closed at $13.17, but opened at $13.79. Orthofix Medical shares last traded at $13.4610, with a volume of 77,899 shares traded. Specifically, major shareholder Engine Capital
Price Targets
Orthofix price target lowered to $15 from $17 at Barrington
$15.00
(was $10.41)
Barrington
Orthofix price target lowered to $15 from $18 at Stifel
$15.00
(was $10.41)
UBS
Orthofix price target lowered to $12 from $14 at TD Cowen
$12.00
(was $10.41)
Cowen & Co.
Orthofix Medical (OFIX) PT Lowered to $18 at Canaccord
$18.00
(was $10.41)
Caitlin Burrows
·
Canaccord Genuity
Orthofix price target lowered to $18 from $22 at Stifel
$18.00
(was $12.46)
Stifel Nicolaus
Orthofix price target raised to $18 from $17 at Barrington
$18.00
(was $14.81)
Michael Petusky
·
Barrington
Orthofix resumed with a Buy at Stifel
$22.00
(was $16.12)
Stifel Nicolaus
Stifel Upgrades Orthofix International (OFIX) to Buy
$24.00
(was $18.22)
Mathew Blackman
·
Stifel Nicolaus
Stifel cuts Orthofix target, says momentum 'faded' during Q2
$31.00
(was $24.11)
Mathew Blackman
·
Stifel Nicolaus